Operator

Good morning, ladies and gentlemen. Welcome to the Veradermics 302 Phase II/III Topline results conference call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Dominic Carrano, Chief Financial Officer of Veradermics. Please go ahead, sir.

Dominic Carrano
CFO & Treasurer

Thank you, operator, and good morning, everyone. Thank you for joining us today to discuss Veradermics' positive top line results from the Phase II/III 302 trial of VDPHL01 in patients with mild-to-moderate pattern hair loss. This morning's press release is available on the Investors section of our website where we will also post the slides used today following the conclusion of this call.

Joining us on the call today are Dr. Reid Waldman, Chief Executive Officer; Mark Neumann, our Chief Commercial and Strategy Officer; and Veradermics' Scientific Advisory Board member, Dr. Maryanne Senna. Dr. Senna is a leading hair loss expert, board-certified dermatologist at Beth Israel Lahey Health and Assistant Professor of Dermatology at Harvard Medical School. She will provide clinical perspective later in the call.

Dr. Waldman will begin with opening remarks and present the results from Part A of Study 302. We will then hear from Dr. Senna for our clinical perspective on the PHL treatment landscape and implications of the results presented today for both patients and their physicians. Mark will then